GU Cancers 2020 | Emerging treatments for mCRPC
Emmanuel Antonarakis, MBBCh, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses emerging treatments for metastatic castration-resistant prostate cancer (mCRPC). Referencing the PROfound (NCT02987543) and VISION (NCT03511664) trials, he specifically focuses on checkpoint inhibitors, PARP inhibitors and PSMA-targeted approaches. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up